Silencing of URG11 expression inhibits the proliferation and epithelial‑mesenchymal transition in benign prostatic hyperplasia cells via the RhoA/ROCK1 pathway

Zhang,Guanying; Zhu,Feng; Han,Guangye; Li,Zeyu; Yu,Quanfeng; Li,Zhenhui; Li,Jianchang

doi:10.3892/mmr.2018.8993

Silencing of URG11 expression inhibits the proliferation and epithelial‑mesenchymal transition in benign prostatic hyperplasia cells via the RhoA/ROCK1 pathway

Authors:
- Guanying Zhang
- Feng Zhu
- Guangye Han
- Zeyu Li
- Quanfeng Yu
- Zhenhui Li
- Jianchang Li
View Affiliations

Affiliations: Second Department of Urinary Surgery, First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, First Department of Urinary Surgery, First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Published online on: May 8, 2018 https://doi.org/10.3892/mmr.2018.8993
Pages: 391-398

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Upregulated gene 11 (URG11) represents a gene upregulated by hepatitis B virus X protein and is involved in the biological processes of multifarious tumors. The present study aimed to investigate the protective effects and regulatory mechanisms of URG11 in benign prostatic hyperplasia (BPH). URG11, Ras homolog family member A (RhoA) and Rho‑associated protein kinase 1 (ROCK1) expression was detected in patients with BPH using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Furthermore, URG11 expression was silenced using URG11‑targeting small interfering RNAs. In addition, cell viability was determined by performing a Cell Counting Kit‑8 assay, and the effect of URG11 on the cell cycle was investigated by flow cytometry. Expression levels of cyclin D1, p27, E‑cadherin, N‑cadherin, vimentin, RhoA and ROCK1 were investigated by RT‑qPCR and western blotting. The results revealed that the expression levels of URG11, RhoA and ROCK1 were enhanced in patients with BPH‑1 cells compared with matched healthy controls. Furthermore, it was demonstrated that transforming growth factor‑β (TGF‑β) induced the proliferation of BPH‑1 cells in vitro, and silencing of URG11 inhibited the effects of TGF‑β on BPH‑1 cell proliferation and the cell cycle. In addition, silencing of URG11 altered the expression levels of cell cycle‑associated genes, epithelial‑mesenchymal transition‑associated genes, and RhoA and ROCK1 protein levels. Thus, the results of the present study suggest that URG11 may be a potential therapeutic target, which may be important to inhibit the development and progression of prostatic hyperplasia.

View Figures

View References

1	Mobley D, Feibus A and Baum N: Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgrad Med. 127:301–307. 2015. View Article : Google Scholar : PubMed/NCBI
2	Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S and Maggi M: Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014:3294562014. View Article : Google Scholar : PubMed/NCBI
3	Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, Fan D and Feitelson MA: Enhanced cell survival of Hep3B cells by the hepatitis B × antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology. 43:415–424. 2006. View Article : Google Scholar : PubMed/NCBI
4	Xie H and Liu J: Increased expression URG11 in hepatocellular carcinoma tissues promotes the growth of hepatocellular carcinoma cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 31:1523–1527. 2015.(In Chinese). PubMed/NCBI
5	Zou X, Li X, Liu J, Lian Z, Fan R, Du R, Xie H, Song J and Fan D: Preparation and characterization of a specific monoclonal antibody against a new gene product: URG11. Hybridoma (Larchmt). 25:378–381. 2006. View Article : Google Scholar : PubMed/NCBI
6	Du R, Xia L, Sun S, Lian Z, Zou X, Gao J, Xie H, Fan R, Song J, Li X, et al: URG11 promotes gastric cancer growth and invasion by activation of beta-catenin signalling pathway. J Cell Mol Med. 14:621–635. 2010.PubMed/NCBI
7	Du R, Huang C, Bi Q, Zhai Y, Xia L, Liu J, Sun S and Fan D: URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin. Biochem Biophys Res Commun. 391:135–141. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shao R, Shi J, Liu H, Shi X, Du X, Klocker H, Lee C, Zhu Y and Zhang J: Epithelial-to-mesenchymal transition and estrogen receptor alpha mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia. Prostate. 74:970–982. 2014. View Article : Google Scholar : PubMed/NCBI
10	Syed V: TGF-β signaling in cancer. J Cell Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
11	Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chew TW, Liu XJ, Liu L, Spitsbergen JM, Gong Z and Low BC: Crosstalk of ras and rho: Activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models. Oncogene. 33:2717–2727. 2014. View Article : Google Scholar : PubMed/NCBI
13	Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, Saint-Geniez M, Campaigniac JP, Liao JK and D'Amore PA: RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010. View Article : Google Scholar : PubMed/NCBI
14	Riou P, Kjær S, Garg R, Purkiss A, George R, Cain RJ, Bineva G, Reymond N, McColl B, Thompson AJ, et al: 14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins. Cell. 153:640–653. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhao ZS and Manser E: PAK and other Rho-associated kinases-effectors with surprisingly diverse mechanisms of regulation. Biochem J. 386:201–214. 2005. View Article : Google Scholar : PubMed/NCBI
16	Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, et al: Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol. 12:457–467. 2010. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Wendt MK, Tian M and Schiemann WP: Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res. 347:85–101. 2012. View Article : Google Scholar : PubMed/NCBI
19	Riento K and Ridley AJ: Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 4:446–456. 2003. View Article : Google Scholar : PubMed/NCBI
20	Hu B, Xu C, Cao P, Tian Y, Zhang Y, Shi C, Xu J, Yuan W and Chen H: TGF-β stimulates expression of chondroitin polymerizing factor in nucleus pulposus cells through the Smad3, RhoA/ROCK1 and MAPK signaling pathways. J Cell Biochem. 119:566–579. 2018. View Article : Google Scholar : PubMed/NCBI
21	Wu ML, Chen CH, Lin YT, Jheng YJ, Ho YC, Yang LT, Chen L, Layne MD and Yet SF: Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 12:222014. View Article : Google Scholar : PubMed/NCBI
22	Mohamed JS and Boriek AM: Stretch augments TGF-beta1 expression through RhoA/ROCK1/2, PTK, and PI3K in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 299:L413–L424. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bechis SK, Otsetov AG, Ge R and Olumi AF: Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 192:16–23. 2014. View Article : Google Scholar : PubMed/NCBI
24	Dong X, Chang ES, Zeng P and Simon MA: Suicide in the global chinese aging population: A review of risk and protective factors, consequences, and interventions. Aging Dis. 6:121–130. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wang W, Guo Y, Zhang D, Tian Y and Zhang X: The prevalence of benign prostatic hyperplasia in mainland China: Evidence from epidemiological surveys. Sci Rep. 5:135462015. View Article : Google Scholar : PubMed/NCBI
26	Lian Z, Liu J, Li L, Li X, Tufan NL, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M and Feitelson MA: Upregulated expression of a unique gene by hepatitis B × antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 5:229–244. 2003. View Article : Google Scholar : PubMed/NCBI
27	Liu ZL, Wu J, Wang LX, Yang JF, Xiao GM, Sun HP and Chen YJ: Knockdown of upregulated gene 11 (URG11) inhibits proliferation, invasion, and β-catenin expression in Non-small cell lung cancer cells. Oncol Res. 24:197–204. 2016. View Article : Google Scholar : PubMed/NCBI
28	Davis FM, Stewart TA, Thompson EW and Monteith GR: Targeting EMT in cancer: Opportunities for pharmacological intervention. Trends Pharmacol Sci. 35:479–488. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim SI, Jung HI and Kim YS: Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 7:24677–24687. 2016. View Article : Google Scholar : PubMed/NCBI
30	Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, Kaanders JH and Bussink J: Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol. 99:344–348. 2011. View Article : Google Scholar : PubMed/NCBI
31	Liu J, Lian Z, Han S, Waye MM, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M, et al: Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene. 25:1008–1017. 2006. View Article : Google Scholar : PubMed/NCBI
32	Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z and Feitelson MA: Epigenetic repression of E-cadherin expression by hepatitis B virus × Antigen in liver cancer. Oncogene. 31:563–572. 2012. View Article : Google Scholar : PubMed/NCBI
33	Riethmacher D, Brinkmann V and Birchmeier C: A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci USA. 92:855–859. 1995. View Article : Google Scholar : PubMed/NCBI
34	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
35	Talar B and Czyz M: TGF-β signaling pathways in cancers. Postepy Hig Med Dosw (Online). 67:1008–1017. 2013.(In Polish). View Article : Google Scholar : PubMed/NCBI
36	Gao J, Zhu Y, Nilsson M and Sundfeldt K: TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 14:722014. View Article : Google Scholar : PubMed/NCBI
37	Surma M, Wei L and Shi J: Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 7:657–671. 2011. View Article : Google Scholar : PubMed/NCBI
38	Marjoram RJ, Lessey EC and Burridge K: Regulation of RhoA activity by adhesion molecules and mechanotransduction. Curr Mol Med. 14:199–208. 2014. View Article : Google Scholar : PubMed/NCBI
39	Lotz-Jenne C, Lüthi U, Ackerknecht S, Lehembre F, Fink T, Stritt M, Wirth M, Pavan S, Bill R, Regenass U, et al: A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor. Oncotarget. 7:25983–26002. 2016. View Article : Google Scholar : PubMed/NCBI